EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nanoform Finland's EBITDA for the
three
months ended in Mar. 2026 was €-2.58 Mil. Nanoform Finland's Revenue for the
three
months ended in Mar. 2026 was €1.27 Mil. Therefore, Nanoform Finland's EBITDA margin for the quarter that ended in Mar. 2026 was -202.20%.
Nanoform Finland (STU:4YL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nanoform Finland EBITDA Margin % Related Terms
Nanoform Finland EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4YL vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Nanoform Finland's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanoform Finland (STU:4YL) has a EBITDA Margin % of -202.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanoform Finland and its competitors. According to the industry distribution chart, Nanoform Finland ranks #632 out of 944 companies in the Biotechnology industry, placing it in the top 66.9%.
Is Nanoform Finland's EBITDA Margin % too high?
Nanoform Finland's current EBITDA Margin % is -202.20%. Based on the distribution chart, Nanoform Finland ranks #632 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #632 out of 944 companies for EBITDA Margin %. This places Nanoform Finland in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanoform Finland and its competitors. Nanoform Finland's current EBITDA Margin % is -202.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (STU:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.82, compared to a current price of €0.77 — trading 57.5% below its estimated fair value. The current EBITDA Margin % is -202.20%. Nanoform Finland's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nanoform Finland (STU:4YL), the current EBITDA Margin % is -202.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (STU:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.77 is trading 57.5% below its estimated GF Value™ of €1.82.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for STU:4YL:
EBITDA Margin %: -202.20%
GF Value™: €1.82 vs. price of €0.77 (57.5% below fair value)
No single metric tells the full story. See the STU:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
73GF Score
Get the complete analysis for STU:4YL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YL has been successfully added to your 
